Disclaimer
Neeman & Industry News
DCGI to implement e-Gov in its working The Drugs Controller General of India (DCGI) to have a single window facility for drug approval soon...
New Indian Regulatory Guidance by Central Drugs Standard Control Organization Guidance for Industry on Submission of Clinical Trial Application for Evaluating Safety and Efficacy - Central Drugs Standard Control Organization...
Indian Clinical Data Management market is expected to ramp up to $150 million MNCs are more than willing to outsource their needs to India because of it\'s technological innovation, creditable quality, operational flexibility, cost effectiveness, time-to-market and competitive advantage according to Koteshwar Govind, Deputy Manager,...
India: Attractive Market for Biopharmaceutical Companies Looking to Accelerate Their Clinical Trials The Clinical Research Market in India is growing at a very rapid rate according to anyone’s statistics…It is exploding according to all the hype. ...

Disclaimer


LEGAL NOTICE

These WebPages are located in the Neeman-medical WWW site ("Site"), which has been registered by Max Neeman, for its use in Internet. These pages are for informational purposes only, and are directed at Pharmaceuticals, Biotech and Medical Device companies.

Even though MAX NEEMAN intends to include accurate and updated information on its Site, MAX NEEMAN makes no warranties or representations as to the nature or accuracy of any material on this Site.

MAX NEEMAN cannot accept any liability for any direct, incidental, consequential, indirect or punitive damages arising out of your access, use or inability to use this Site or any WebPages linked to this Site, or any errors or omissions in the content thereof.

Unless indicated otherwise, MAX NEEMAN owns all intellectual property rights on the content of this Site. These WebPages and/or their content, including text, images or HTML codes, are not to be fixed, reproduced, retransmitted, modified, distributed, reused, re-posted, made accessible or otherwise used or exploited without prior written authorization of MAX NEEMAN, other than by downloading and viewing in a single unit, and/or printing a single hard copy, for private business only. Users shall be fully liable for any use of the material on this Site which is protected by intellectual property rights.

Access to the information contained in this Site from a jurisdiction where its content may be deemed illegal is not authorized. All users who decide to access to the information contained in this Site will do so at their own risk and shall be liable for the compliance with any local laws that may be applicable.